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Lithium has been used in medicine for more than
a century and was used by Garrod [1] for the treat-
ment of gout and rheumatism. Toxic effects (diar-
rhea, nausea, anorexia, vomiting, muscle weak-
ness, dizziness, tremor, polyuria, oliguria, and stiff-
ness in cats and dogs) were reported early in this
century by Good [2] and Cleaveland [3], and some
of the physiologic effects of lithium were described
[4]. The use of lithium was generally discarded until
1949 when Cade [5] reported its use and ef-
fectiveness in the treatment of mania. Confirmation
of these reports [6, 7] has led to the widespread use
of lithium in psychiatric practice, and it is regarded
as an indispensable and major drug in the psychia-
trists' therapeutic armentarium [8].
Lithium is an element in the periodic table in the
same group as sodium and potassium, and it is not
surprising that a large number of side-effects have
been reported [9, 10]. Some of these effects may be
due to replacement of sodium or potassium in the
plasma or cell, but many appear to be a direct effect
of the ion [11, 12].
In this review, we will discuss the general effects
on the body of lithium, including the pathologic le-
sions that exist in the kidney and a detailed review
of the effects of lithium on electrolyte and water ex-
cretion.
Lithium metabolism
Weak solutions of lithium are readily absorbed
from the gastrointestinal tract and almost all of the
absorbed lithium is excreted in the urine [11, 13].
Fifteen minutes after its ingestion lithium appears in
the urine, and its excretion reaches a maximum at
about 1.5 hours [11]. Lithium is removed from the
plasma by renal excretion and by entering into cells
and other body compartments [14]. Thus, there is
rapid excretion of lithium from plasma and a slow
excretory phase reflecting its excretion from the
whole body pool [11]. Excretion of lithium is im-
paired and the half-life is prolonged in people with
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renal impairment [15, 16]. In elderly people, its half-
life is prolonged [7], probably reflecting the decline
in nephron numbers and renal function that occurs
with ageing.
Lithium is handled by the kidney in a manner
similar to that of sodium. It is filtered and is reab-
sorbed in the proximal tubule [17]. It is almost cer-
tainly reabsorbed by the loop of Henle, because
frusemide increases the fractional excretion of lith-
ium [18]. This may explain the corticomedullary
gradient that is found for lithium [19]. Chronic
frusemide administration does not alter lithium ex-
cretion in the urine, but this is probably due to the
balance between the decreased ioop of Henle and
the increased proximal tubule reabsorption due to
volume changes [20]. Whether lithium is reabsorbed
or excreted to a major extent in the distal nephron
[12, 16, 17, 21—23] is controversial. Many of the re-
ported effects may result from a change in sodium
balance and alterations in the proximal tubule reab-
sorption of lithium.
The most important way that lithium excretion is
altered is by the changing proximal tubule absorp-
tion of salt and water [24, 25]. If the proximal tubule
absorbs more water on a fractional or absolute
basis, more lithium is also absorbed. Thus, it would
be predicted that a low salt diet, volume depletion,
cardiac failure, thiazide diuretics, and other events
that lead to increased proximal tubule reabsorption
of salt and water would all lead to increased plasma
concentrations of lithium [26]. Conversely, infusion
of saline together with frusemide should increase
the rate of excretion. This, however, will only act
on the lithium in plasma, and excretion of the rest of
the lithium in the body depends on its release from
other compartments into the plasma [4].
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Lithium is present in most body tissues [4, 7].
Kidney [7], thyroid [27], and brain [7] are some of
the organs with a higher intracellular than extra-
cellular lithium concentration.
General effects on the body
Lithium is ubiquitous in its distribution, and ef-
fects have been reported on most body tissues. Side
effects requiring cessation of its therapy have been
reported for most major systems (Table 1).
A large number of central nervous system effects
have been reported. Certain side effects may be due
to replacement of sodium or potassium in the cell.
But its therapeutic effect and many side effects are
probably due to a specific effect of the lithium ion.
Lithium does interfere with the adenyl cyclase and
cyclic AMP system, which is a possible explanation
for a large number of its effects. It has been report-
ed to inhibit stimulated adenyl cyclase activity in
kidney [28—30], thyroid [31], hypothalamus [32],
lymphocytes [33], and the effects on the first three
all have clinical counterparts in clinical disorders of
these organs [34-40].
Lithium in high doses both in man and animals
produces a very large number of metabolic effects.
If the plasma concentration is maintained below 0.6
mmoles/liter, the clinical expression of these effects
are minimized and the therapeutic effect is main-
tained [41]. Most biochemical and clinical effects of
lithium are reversed when use of the drug is ceased
and it is eliminated from the body [10, 11, 25, 34—36,
42, 43]. There are some reports of subsequent mor-
phologic and structural changes that may lead to
permanent damage. These have been most widely
reported in the kidney [44, 45].
Morphologic and pathologic effects on the kidney
(Table 2)
Individual case reports exist of morphologic
changes associated with prolonged lithium adminis-
tration [44-49]. These changes usually consist of
ballooning and vacuolation of the cytoplasm [45]
with pyknotic nuclei [45, 46]. Tubular cells show
desquamation [45, 46], usually in the distal and con-
voluted tubules. This may result in the development
of focal nephron atrophy [45] and may cause scle-
rosis in some glomeruli [44, 45]. Changes in the as-
cending loop of Henle are noted [46], and minor
changes are present in the proximal tubular epithe-
hum [45]. Interstitial fibrosis [44, 45], interstitial cel-
lular infiltrate [49], and interstitial edema [47], as
well as slight thickening and hyalinosis of arteriolar
walls, are also noted [44].
The association of the incidences of such lesions
and high lithium dose or prolonged use of lith-
ium is unclear. Kincaid-Smith et a11 have begun a
large biopsy survey of this problem and have found
as many lesions in a control group of people with
similar psychiatric disorders who have not received
lithium. These patients receive a multitude of drugs,
and some other agent could be responsible. The
whole problem of whether morphologic and patho-
logic changes result from lithium administered in
doses that maintain plasma lithium levels in a thera-
peutic range below 1.0 mmoles/liter needs urgent in-
vestigation. There is, however, little doubt that a
high dose of lithium will produce acute morphologic
lesions in both humans [47, 48] and animals [25, 50].
The relationship of these to chronic changes [44, 45]
is unknown, but it is of interest that certain of these
changes are similar to those seen in the presence of
hypokalemia, which may (though debated) cause
chronic interstitial changes [55]. Evan and Ollerich
administered high doses of lithium to rats and de-
scribed lesions that occurred throughout the renal
tubules [51] but were most marked in the collecting
ducts and the distal tubule. With higher doses of
lithium, changes were also seen in the loop of Henle
'Communications.
Table 1. Clinical and biochemical effects of lithiuma
Nervous system:
Renal system:
Cardiovascular system:
Gastrointestinal:
Endocrine:
Dermatologic:
Hemotologic:
Transpiacental:
Tremor
Muscle weakness
Headache
Ataxia
Blurred vision
Toxic confusional state
Drowsiness
Inhibits opiate receptor binding in
brain [81]
Polyuria, inhibits vasopressin
stimulated adenyl cyclase
Polydipsia
Morphologic changes
Increases renin [82]
Increases urinary prostaglandins [83]
Atrial arrythmias [84]
Cardiac failure [85]
T-wave inversion
Hypotension
Anorexia, nausea
Vomiting
Diarrhea
Increases ADH and All [86]
Hypothyroidism with goiter
Inhibits TSR-stimulated cAMP
Increases aldosterone with adrenal
hyperplasia
Decreases sperm motility
Glucose intolerance [87]
Decreases ACTH variation [88]
Acne [89]
Neutrophilia [90, 91]
Augments lymphocyte proliferative
response to phytohemagglutinin [33]
Reinduction of acute myeloblastic
leukemia [92]
Lithium poisoning [93, 94]
a See also Refs. 4, 7, 9, tO, 16, 26, 88, 93.
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Table 2. Microscopic lesions in the kidney during lithium administration in animals and man
Ref. no. Lithium Site of lesion and pathological change
Animal studies
2]
[52]
[54]
[50]
[25]
[51]
Lithium dose
mg/kg/day
60
6Oto 180
50
20 to 100
21 to 428
10 to 100
No lesions a
Nolesionsa
Nolesionsa
Distal tubule, collecting ducts, loop of Henle. Slight to moderate
dilation of tubules, desquamative epithelium. Moderate amount of fat
in affected tubules.
Proximal tubule. Dilated tubules with cellular debris.
Extensive mitochondrial swelling and dilation of cisternel in all
parts of nephron, distal tubule, and collecting ducts show karyolysis
and cytoplasmic rarefraction.
Human studies
[53]
[45]
[44]
[49]
[46]
[47]
[48]
Maximum serum
lithium level
mEq/liter
1.3
No episodes of
toxicity
0.8 to 4.5
Toxicity present
1.2
4.6
5.2
No lesionsa (proteinuria present).
Vacuolated cells in distal convoluted tubule and collecting ducts
containing unique PAS-positive material prominent in medulla region.
Minor changes in proximal tubule. Cellular desquamation.
Focal nephron atrophy, focal interstitial fibrosis, glomerular
sclerosis, minor arteriolar hyalinization, no cellular desquamation.
Small cysts and granular scarring noted macroscopically.
Focal distal tubular damage with basement membrane ruptures, inter-
stitial cell infiltrate.
Collecting ducts and distal tubules show desquamation, pyknotic
irregular nuclei also in ascending limb of loop of Henle.
Distal tubule. Interstitial edema.
Dilated convoluted tubules, capsular proliferation adhesion, and
glomerular sclerosis. Proximal tubule cell vacuolation.
a Several authors [2, 52-54] have not reported renal changes after lithium administration. The details to support this observation are
incomplete, however, and in some instances may be related to low doses.
and the proximal tubule [51]. The extent and severi-
ty of the lesion varied with the dose of lithium and
its duration of administration [51]. There was
marked mitochondrial swelling and dilation of the
rough endoplasmic reticulum. In man, similar struc-
tural changes can be shown in patients who have
symptoms of lithium toxicity, and these patients
can have marked disturbances of renal function [46,
48]. In rats, polyuria almost invariably precedes le-
thal toxicity [25], but its precise relationship to the
ultrastructural changes are uncertain. It has been
suggested that if the dose of lithium is left low then
the incidence of polyuria can be reduced and renal
lesions may not result [41]. Further evidence is
needed to confirm this hypothesis, but there is no
real evidence to support the concept that lithium is
the cause of chronic renal morphologic changes.
Effects of lithium on the kidney
The most common and probably most important
side effect of lithium is polyuria [11, 40], which may
develop into a full blown syndrome indistinguish-
able by usual criteria from diabetes insipidus [34—
36, 39, 40]. The high-volume, low-urine osmolality
does not respond to antidiuretic hormone [39, 40],
and thus this diabetes insipidus is classified as neph-
rogenic in origin. The mechanism of this has been
debated, and there is conflicting evidence, some of
which may result from the comparison of results
from different experimental models that are not
strictly comparable.
Polyuria could result from interference with renal
function at many sites. Suppression of salt and wa-
ter reabsorption in the proximal tubule, loop of
Henle, distal tubule, and collecting ducts can all
cause polyuria, but by definition it is only the sup-
pression of ADH-induced water reabsorption that
will lead to diabetes insipidus. That is, it is only if
the distal nephron (collecting tubules and collecting
ducts) is "impermeable" to water that the full
blown syndrome can result. Thus, although effects
of lithium may be demonstrated on transport pro-
cesses besides the ADH-mediated one, these can at
best be contributing to the full blown syndrome
rather than causing it.
A large number of effects of lithium on urinary
excretion of electrolytes have been reported, and
the site of these effects have been confirmed by mi-
cropuncture experiments [56]. Some of the effects
of lithium on water and electrolytes in animals and
man are presented in Table 3.
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Table 3. Effects of lithium on water and electrolytes in animals and mana
Urine Plasma
Body
compartmentsAcute Chronic Acute Chronic
Sodium C [11, 14, 15,
56, 63, 68]
—[61,71]
J, [11,58,68]
.—[25]
, [11, 14]
1' [50]
[11,25,29,41,
50, 68, 70]
J, [11,25,50]
— Exchangeable
sodium [70]
Extracellular
sodium [70]
Potassium C [11, 14, 22, C [29,57]
56, 63]
'-[61]
C [11,25]
'-[14]
[11,50]
'-[1l,25,29,41,
50, 68, 70]
Totalbodypo-
tassium [34]
[50,58]
pH 1' [11,59,73] C [11] C [11]
— [73]
Calcium C [65] C [58, 65]
[59]
C [66] C [64,71]
[41, 58, 62]
Phosphate
[71,72]
C [57]
.—[41,58,62,71] —[57,58,62,64]
Chloride C [11,56, 63]
[58]
[11]
Bicarbonate C [59,63] C [11]
[63]
[59]
[41]
Osmolality
[41,69]
[56] [29, 30, 40, 43,
57, 58, 74]
C [50]
—[29,69,74]
Water [41,61] C Total body
Ability to increase [56, 60, 63, 68] [39, 40, 43, 50, water [70]
free water reabsorption 57, 74]
Ability to increase C Intracellular
free water clearance J [60] - [39, 57] water [70]
a This table is a review of selected papers that report the effects of lithium on water and electrolytes in urine and plasma. It is intended
to show that lithium has a large number of effects under differing experimental conditions. The difference in experimental conditions and
methods used may explain certain apparent contradictions in the findings. Numbers in brackets refer to references cited. C denotes in-
crease; ]. denotes decrease; — denotes no change.
The acute infusion of lithium or its oral adminis-
tration affects the handling of a number of com-
pounds. Frequently, these have been interpreted as
being specific effects of lithium [11, 12]. But, if a
control is used to which the same amount of sodium
salt is given, a similar pattern appears. Studies done
recently in our laboratory show that the acute ef-
fects of sodium and lithium loads are virtually iden-
tical. Changes in sodium excretion, potassium ex-
cretion, water excretion, phosphate excretion, and
others can all be explained by a "volume-induced"
depression of proximal tubule function. Most obser-
vations made in micropuncture experiments [56] are
capable of a similar interpretation. Lithium does
cause changes in potassium excretion [11], and it
has been postulated that polyuria and the morpho-
logic changes may result from hypokalemia [34].
There is, however, no experimental or direct clini-
cal evidence to support this hypothesis. In view of
the inconsistent effect lithium has on plasma cal-
cium, alterations in calcium cannot account for the
polyuria.
In man and rats, the polyuria is resistant to vaso-
pression [39, 40] and to mineralocorticoid [50] ad-
ministration. Levels of ADH circulating in plasma
are high when measured by radioimmunoassay [41,
46, 74]. Biologic assay of plasma is not possible due
to lack of assay sensitivity, in patients on lithium
therapy, ADH levels are elevated compared with
control patients [41, 69]. These results infer that
ADH production is normal and, in fact, is above
normal subsequent to dehydration, but ADH is un-
able to exert its effect on the kidney.
The evidence from human and whole animal stud-
ies infers that the defect is due to lack of response of
the kidney to ADH [29, 39, 40, 75], but in vitro data
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does not at first review support this suggestion [30,
76].
Bentley and Wasserman [76] were unable to dem-
onstrate any effect of lithium on osmotically in-
duced water permeability in response to ADH in
vitro using toad bladder. In an extensive series of
experiments in the rat, Carney, Rayson and Morgan
[30] were unable to show any effect of lithium on the
response of osmotic or diffusional water per-
meability to ADH. Pretreatment of rats with lithium
or addition of lithium to the medium or perfusate
did not alter the increase in water permeability in-
duced by antidiuretic hormone. Evaluation of the
data and experiments recently performed by us pro-
vide an explanation for this divergence between our
previous results and those seen in vivo.
In a recent series of experiments in our laborato-
ry, renal papillae were taken from normal or from
lithium-pretreated rats that had developed polyuria.
The papillae were incubated in artificial plasma, in
plasma from control animals, and in plasma from
rats with polyuria due to lithium. The permeability
to water in papillae incubated in plasma was higher
than it was in papillae incubated in artificial media,
but permeability to water did not differ when in-
cubated in plasma from control or lithium-treated
animals. When ADH was added, there was an in-
crease in the diffusional water permeability in the
papillae in the normal plasma. The rise in dif-
fusional water permeability in papillae incubated in
plasma from rats pretreated with lithium was im-
paired (Fig. 1). This result inferred that some factor
in plasma from rats pretreated with lithium inter-
fered with ADH action. The interference was not
due to lithium alone but required the presence of
plasma from these lithium-treated animals. In whole
animal experiments, we have confirmed that rats
with lithium-induced polyuria have a depressed re-
sponse to low doses of vasopressin. A normal re-
sponse can be obtained, however, with higher
doses.
Thus, the defect would appear to be due to a
plasma substance that either binds ADH or results
in the secretion of ADH in an altered or inactive
form that then competes with ADH for receptor
sites at the distal nephron. Such an explanation
would resolve the differences between in vivo and
in vitro results. It would also explain why cyclic
AMP has an effect on polyuria greater than that of
ADH [57].
If the hypothesis suggested above is correct,
there is no specific need for any other action to ex-
plain the polyuria. Lithium does, however, interfere
with generation of cyclic AMP, and this has been
confirmed by a number of workers [28, 32, 39, 40].
Although this may be observed, it is not the key
phenomenon, as cyclic AMP production following
ADH was suppressed in vitro (Carney et al [30]),
and at the same time a full permeability response to
ADH was obtained. Thus, this effect might amplify
the effect proposed above. Other effects may occur
on other factors that mediate changes in water per-
meability. Thus, lithium inhibits catecholamine-in-
duced antidiuresis [77], and in platelets it alters the
effects of prostaglandin on cyclic AMP generation
[78]. Similar effects in the kidney could lead to de-
fects in water handling and polyuria.
Summary. Lithium has many important actions
on the kidney. It induces an initial polyuria and al-
teration in salt, water, and electrolyte handling due
to its ionic similarity to sodium. This effect is com-
pensated by a series of physiologic changes. In ad-
dition, resistance to the action of endogenous and
exogenous ADH develops probably due to a circu-
lating competitor (or binder) of ADH. Associated
with this polyuria but uncertain as to the direct mor-
phologic functional correlation, there is develop-
ment of structural changes in the kidney in mito-
chondria and rough endoplasmic reticulum [51].
Even less well associated is a chronic interstitial
Artificial medium
Normal rat plasma
Lithium—treated
rat plasma
U
>
-o
a,
E
a,
a-
a,
50 200
Concentration of ADH, jUrnI1
Fig. 1. Diffusional permeability to water measured in the pres-
ence and absence of ADH. The clear bars indicate the per-
meability in the absence of ADH, and the hatched or dotted bars
represent the increment due to ADH. Papillae incubated in
plasma from lithium-treated rats showed an impairment in the
response to ADH though the same maximum response was able
to be shown with high concentrations. The dose response to
ADH is shifted to the right.
20 2000
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and glomerular lesion that develops in a certain
number of patients on clinical therapy [44, 45].
Lithium has many toxic effects, the principal and
most frequent being those on the kidney, but be-
cause it is an exceedingly useful drug [79] in the
therapy of a wide variety of psychiatric conditions
[9], its use is essential. Nevertheless, it is essential
that the blood level of the drug is strictly controlled
to reduce the incidence of side effects of polyuria
and of renal damage.
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